News
QNTM
4.108
+5.86%
0.228
Weekly Report: what happened at QNTM last week (0330-0403)?
Weekly Report · 2d ago
Quantum BioPharma Cleared to Proceed With $700 Million Market Manipulation Lawsuit After Motion to Dismiss Largely Denied
TipRanks · 6d ago
Quantum BioPharma Announces U.S. District Court For The Southern District Of New York Rules Against CIBC World Markets, RBC Dominion Securities Joint Motion To Reject Quantum's Lawsuit
Benzinga · 6d ago
QUANTUM BIOPHARMA: WINS COURT CHALLENGE IN $700 MLN CLAIM AS DEFENDANTS JOINT MOTION TO DISMISS LAWSUIT ALLEGING MARKET MANIPULATION BY CIBC & RBC
Reuters · 6d ago
Quantum BioPharma wins court fight as judge rejects bid to dismiss USD 700 million suit
Reuters · 6d ago
Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis
TipRanks · 04/01 12:44
Quantum BioPharma submits Lucid-21-302 new drug application to the FDA
TipRanks · 04/01 12:25
Quantum BioPharma Submits IND Application To FDA For Lucid-21-302, Its New Drug Candidate For Treatment Of Multiple Sclerosis
Benzinga · 04/01 12:09
Quantum BioPharma submits FDA IND for Lucid-MS Phase 2 trial in multiple sclerosis
Reuters · 04/01 12:04
QUANTUM BIOPHARMA LTD - PHASE 2 INTERIM DATA FOR LUCID-MS PROJECTED FOR Q4 2026
Reuters · 04/01 12:02
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
Barchart · 04/01 07:02
Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS
TipRanks · 03/30 13:07
Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial
TipRanks · 03/30 12:28
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 03/30 12:05
Quantum BioPharma Enters Into Binding LOI With Allucent To Support Planned Phase 2 Clinical Trial Of Lucid-MS For Treatment Of Multiple Sclerosis
Benzinga · 03/30 11:54
Quantum BioPharma signs LOI with Allucent for Lucid-MS Phase 2 trial in multiple sclerosis
Reuters · 03/30 11:51
QUANTUM BIOPHARMA SIGNS BINDING LETTER OF INTENT WITH ALLUCENT TO CONDUCT PHASE 2 CLINICAL TRIAL IN MULTIPLE SCLEROSIS
Reuters · 03/30 11:50
Weekly Report: what happened at QNTM last week (0323-0327)?
Weekly Report · 03/30 10:25
Quantum Biopharma grants 35,000 stock options; exercise price rises to CAD 6.50
Reuters · 03/27 23:30
QUANTUM BIOPHARMA PROVIDES CORPORATE UPDATE
Reuters · 03/27 23:30
More
Webull provides a variety of real-time QNTM stock news. You can receive the latest news about Quantum BioPharma Ltd through multiple platforms. This information may help you make smarter investment decisions.
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.